Article Data

  • Views 436
  • Dowloads 133

Original Research

Open Access

Association of estrogen receptor-beta (ESR2) polymorphism and cancer risk: a meta-analysis

  • Wenkai Xia1
  • Tianyi Wang2
  • Dong Sun1
  • Weidong Mao3
  • Xiangcheng Xie4,*,

1Department of Nephrology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Wuxi, China

2Yangzhou University of Medicine, Yangzhou, Jiangsu, China

3Department of Oncology, Jiangyin People's Hospital, Jiangyin, China

DOI: 10.12892/ejgo3014.2016 Vol.37,Issue 4,August 2016 pp.530-538

Published: 10 August 2016

*Corresponding Author(s): Xiangcheng Xie E-mail: freemaple@126.com

Abstract

Estrogen signal medicated by estrogen receptor (ER), which is involved in various diseases related to steroid hormone, such as cancer. A number of association studies have focused on ESR2 polymorphisms to investigate the relationship with cancer risk. However, the results are inconsistent and inconclusive. To examine this controversy, 33 studies were enrolled for the pooled analysis for three polymorphisms (rs3020450, rs4986938, and rs1256049) in cancer risk using odds ratios (ORs) with 95% confidence intervals (CIs). Regarding rs4986938, A allele was associated with decreased breast cancer. Ethnicity subgroup analysis observed a decreased risk in both Asian and Caucasian descendent. Regarding rs1256049, cancer type subgroup analysis revealed a significant association with increased prostate and endometrial cancer risk. rs3020450 was not associated with cancer risk in any model. Further studies for clarifying the roles of ESR2 polymorphisms in cancer risk seem of vital importance.

Keywords

ESR2; Polymorphism; Cancer risk; Meta-analysis.

Cite and Share

Wenkai Xia,Tianyi Wang,Dong Sun,Weidong Mao,Xiangcheng Xie. Association of estrogen receptor-beta (ESR2) polymorphism and cancer risk: a meta-analysis. European Journal of Gynaecological Oncology. 2016. 37(4);530-538.

References

[1] Pharoah P.D., Dunning A.M., Ponder B.A., Easton D.F.: “Association studies for finding cancer-susceptibility genetic variants”. Nat. Rev. Cancer, 2004, 4, 850.

[2] Chen Y.C., Kraft P., Bretsky P., Bretsky P., Hunter D.J., Albanes D., et al.: “Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium”. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 1973.

[3] Yager J.D., Davidson N.E.: “Estrogen carcinogenesis in breast cancer”. N. Engl. J. Med., 2006, 354, 270.

[4] Menasce L.P., White G.R., Harrison C.J., Boyle J.M.: “Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique”. Genomics,1993, 17, 263.

[5] Enmark E., Pelto-Huikko M., Grandien K., Laqercrantz S., Laqercrantz J., Fried G., et al.: “Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern”. J. Clin. Endocrinol. Metab., 1997, 82, 4258.

[6] Mosselman S., Polman J., Dijkema R.: “ER beta: identification and characterization of a novel human estrogen receptor”. FEBS Lett., 1996, 392, 49.

[7] Goulart A.C., Zee R.Y., Rexrode K.M.: “Association of estrogen receptor 2 gene polymorphisms with obesity in women (obesity and estrogen receptor 2 gene)”. Maturitas, 2009, 62, 179.

[8] Pirskanen M., Hiltunen M., Mannermaa A., Helisalmi S., Lehtovirta M., Hänninen T., Soininen H.: “Estrogen receptor beta gene variantsare associated with increased risk of Alzheimer's disea se in women”. Eur. J. Hum. Genet., 2005, 13, 1000.

[9] Eastwood H., Brown K.M., Markovic D., Pieri L.F.: “Variation in the ESR1 and ESR2 genes and genetic susceptibility to anorexia nervosa”. Mol. psychiatry, 2002, 7, 86.

[10] Handoll H.H.: “Systematic reviews on rehabilitation interventions”. Arch. Phys. Med. Rehabil., 2006, 87, 875.

[11] Midgette A.S., Wong J.B., Beshansky J.R., Porath A., Fleming C., Pauker S.G.: “Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction”. Med. Decis. Making, 1994, 14, 108.

[12] MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk: “Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy”. Int. J. Cancer, 2010, 126, 2935.

[13] Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al.: “Estrogen receptor polymorphisms and the risk of endometrial cancer”. BJOG, 2009, 116, 1053.

[14] Chae Y.K., Huang H.Y., Strickland P., Hoffman S.C., Helzlsouer K: “Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer”. PloS One, 2009, 4, e6523.

[15] Breast and Prostate Cancer Cohort Consortium, Cox D.G., Bretsky P., Kraft P., Pharoah P., Albanes D., et al.: “Haplotypes of the estrogen receptor beta gene and breast cancer risk”. Int. J. Cancer, 2008, 122, 387.

[16] de Giorgi V., Sestini S., Gori A., Mazzotta C., Grazzini M., Rossari S., et al.: “Polymorphisms of estrogen receptors: risk factors for invasive melanoma - a prospective study”. Oncology, 2011, 80, 232.

[17] Ferlin A., Ganz F., Pengo M., Selice R., Frigo A.C., Foresta C: “Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes”. Endocr. Relat. Cancer, 2010, 17, 17.

[18] Fischer C., Juhasz-Boess I., Lattrich C., Ortmann O., Treeck O: “Estrogen receptor beta gene polymorphisms and susceptibility to uterine fibroids”. Gynecol. Endocrinol., 2010, 26, 4.

[19] Forsti A., Zhao C., Israelsson E., Dahlman-Wright K., Gustafsson J.A., Hemminki K: “Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association”. Breast Cancer Res. Treat., 2003, 79, 409.

[20] Fukatsu T., Hirokawa Y., Araki T., Hioki T., Murata T., Suzuki H., et al.: “Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population”. Anticancer Res., 2004, 24, 2431.

[21] Gallicchio L., Berndt S.I., McSorley M.A., Newschaffer C.J., Thuita L.W., Argani P., et al.: “Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease”. BMC Cancer, 2006, 6, 173.

[22] Iwasaki M., Hamada G.S., Nishimoto I.N., Netto M.M., Motola J. Jr., Laginha F.M., et al.: “Isoflavone, polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians”. Cancer Sci.,2009, 100, 927. [23] Lattrich C., Haring J., Schuler S., Skrzypczak M., Ortmann O., Treeck O.: “Polymorphisms in the promoter region of estrogen receptor beta gene in endometrial cancer”. Arch. Gynecol. Obstet., 2014, 289, 631.

[24] Lim W.Y., Chen Y., Chuah K.L., Eng P., Leong S.S., Lim E., et al.: “Female reproductive factors, gene polymorphisms in the estrogen metabolism pathway, and risk of lung cancer in Chinese women”. Am. J. Epidemiol., 2012, 175, 492.

[25] Lurie G., Wilkens L.R., Thompson P.J., McDuffie K.E., Carney M.E., Terada K.Y., et al.: “Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma”. Cancer Causes Control, 2009, 20, 47.

[26] Maguire P., Margolin S., Skoglund J., Sun X.F., Gustafsson J.A., Børresen-Dale A.L., et al.: “Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer”. Breast Cancer Res. Treat., 2005, 94, 145.

[27] Nicolaiew N., Cancel-Tassin G., Azzouzi A.R., Grand B.L., Mangin P., Cormier L., et al.: “Association between estrogen and androgen receptor genes and prostate cancer risk”. Eur. J. Endocrinol., 2009, 160, 101.

[28] Park S.K., Andreotti G., Rashid A., Chen J., Rosenberg P.S., Yu K., et al.: “Polymorphisms of estrogen receptors and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China”. Carcinogenesis, 2010, 31, 842.

[29] Paulus J.K., Zhou W., Kraft P., Johnson B.E., Lin X., Christiani D.C.: “Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women”. Lung Cancer, 2011, 71, 258.

[30] Rudolph A., Sainz J., Hein R., Hoffmeister M., Frank B., Försti A., et al.: “Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes”. Endocr. Relat. Cancer, 2011, 18, 371.

[31] Safarinejad M.R., Safarinejad S., Shafiei N.: “Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men”. Mol Carcinog., 2012, 51, E104.

[32] Schuler S., Lattrich C., Skrzypczak M., Fehm T., Ortmann O., Treeck O.: “Polymorphisms in the promoter region of ESR2 gene and susceptibility to ovarian cancer”. Gene, 2014, 546, 283.

[33] Setiawan V.W., Hankinson S.E., Colditz G.A., Hunter D.J., De Vivo I.: “Estrogen receptor beta (ESR2 ) polymorphisms and endometrial cancer (United States)”. Cancer Causes Control, 2004, 15, 627.

[34] Sonestedt E., Ivarsson M.I., Harlid S., Ericson U., Gullberg B., Carlson J., et al.: “The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes”. J. Nutr., 2009, 139, 993.

[35] Sonoda T., Suzuki H., Mori M., Tsukamoto T., Yokomizo A., Naito S., et al.: “Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men”. Eur. J. Cancer Prev., 2010, 19, 131.

[36] Srivastava A., Sharma K.L., Srivastava N., Misra S., Mittal B.: “Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy”. PloS One, 2012, 7, e40162.

[37] Treeck O., Elemenler E., Kriener C., Horn F., Sprinqwald A., Hartmann A., Ortmann O.: “Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility”. J. Steroid. Biochem. Mol. Biol., 2009, 114, 207.

[38] Duval S., Tweedie R.: “Trim and fill: a simple funnel-plot- basedmethod of testing and adjusting for publication bias in meta-analysis”. Biometrics, 2000, 56, 455.

[38]Sun Y.H., Yang B., Wang X.H., Xu C.L., Gao X.F., Gao X., Wang L.H.: “Association between single-nucleotide polymorphisms in estrogen receptor beta gene and risk of prostate cancer”. Chin. J. Surg., 2005, 43, 948.

[39]Wang J.Y., Zhang H.Z., Guan Y.Q., Xie F.: “Relationship of Estrogen Receptor βGene Polymorphisms with Leiomyoma of the Uterus in Han Population”. J. of Cap. Med. Univer., 2010, 31, 660.

[40] Huang H.L., Zhao Q.Z., Xie J.S., Fang X.Y.: “Correlation between estrogen receptor gene polymorphism and estrogen receptor expression in endometrial cancer”. Mater. Child Heal Care of China, 2013, 28, 2772.

[41] Zhang W., Shi D., Du C.Y., Luo F.: “Association between Rsal and Alul polymorphism in the estrogen receptor beta gene and primary hepatocellular carcinoma”. Chin. J. Hepatol., 2009, 17, 99.

[43] Ribeiro J.R., Freiman R.N.: “Estrogen signaling crosstalk: Implicationsfor endocrine resistance in ovarian cancer”. J. Steroid Biochem. Mol. Biol., 2014, 143, 160.

[44] Dey P., Jonsson P., Hartman J., Williams C., Strom A., Gustafsson J.A.: “Estrogen receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3”. Mol. Endocrinol., 2012, 26, 1991.

[45] Ellem S.J., Risbridger G.P.: “The dual, opposing roles of estrogen in the prostate”. Ann. N. Y. Acad. Sci., 2009, 1155, 174.

[46] Herrington D.M., Howard T.D., Brosnihan K.B., McDonnell D.P., Li X., Hawkins G.A., et al.: “Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein”. Circulation, 2002, 105, 1879.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top